Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs.

Diamond JM, Vanpouille-Box C, Spada S, Rudqvist NP, Chapman JR, Ueberheide BM, Pilones KA, Sarfraz Y, Formenti SC, Demaria S.

Cancer Immunol Res. 2018 Jun 15. doi: 10.1158/2326-6066.CIR-17-0581. [Epub ahead of print]

PMID:
29907693
2.

Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.

Rudqvist NP, Pilones KA, Lhuillier C, Wennerberg E, Sidhom JW, Emerson RO, Robins HS, Schneck J, Formenti SC, Demaria S.

Cancer Immunol Res. 2018 Feb;6(2):139-150. doi: 10.1158/2326-6066.CIR-17-0134. Epub 2017 Nov 27.

PMID:
29180535
3.

Barriers to Radiation-Induced In Situ Tumor Vaccination.

Wennerberg E, Lhuillier C, Vanpouille-Box C, Pilones KA, García-Martínez E, Rudqvist NP, Formenti SC, Demaria S.

Front Immunol. 2017 Mar 13;8:229. doi: 10.3389/fimmu.2017.00229. eCollection 2017. Review.

4.

CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy.

Pourchet A, Fuhrmann SR, Pilones KA, Demaria S, Frey AB, Mulvey M, Mohr I.

EBioMedicine. 2016 Jan 19;5:59-67. doi: 10.1016/j.ebiom.2016.01.022. eCollection 2016 Mar.

5.

In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment.

Vanpouille-Box C, Pilones KA, Wennerberg E, Formenti SC, Demaria S.

Vaccine. 2015 Dec 16;33(51):7415-7422. doi: 10.1016/j.vaccine.2015.05.105. Epub 2015 Jul 3. Review.

6.

TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity.

Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS, Formenti SC, Barcellos-Hoff MH, Demaria S.

Cancer Res. 2015 Jun 1;75(11):2232-42. doi: 10.1158/0008-5472.CAN-14-3511. Epub 2015 Apr 9.

7.

Combination of radiotherapy and immune checkpoint inhibitors.

Pilones KA, Vanpouille-Box C, Demaria S.

Semin Radiat Oncol. 2015 Jan;25(1):28-33. doi: 10.1016/j.semradonc.2014.07.004. Review.

PMID:
25481263
8.

Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes.

Pilones KA, Aryankalayil J, Babb JS, Demaria S.

J Immunother Cancer. 2014 Oct 14;2(1):37. doi: 10.1186/s40425-014-0037-x. eCollection 2014.

9.

The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation.

Demaria S, Pilones KA, Vanpouille-Box C, Golden EB, Formenti SC.

Radiat Res. 2014 Aug;182(2):170-81. doi: 10.1667/RR13500.1. Epub 2014 Jun 17. Review.

10.

Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment.

Demaria S, Pilones KA, Formenti SC, Dustin ML.

Oncoimmunology. 2013 Mar 1;2(3):e23127.

11.

Invariant NKT cells as novel targets for immunotherapy in solid tumors.

Pilones KA, Aryankalayil J, Demaria S.

Clin Dev Immunol. 2012;2012:720803. doi: 10.1155/2012/720803. Epub 2012 Oct 17. Review.

12.

Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.

Ruocco MG, Pilones KA, Kawashima N, Cammer M, Huang J, Babb JS, Liu M, Formenti SC, Dustin ML, Demaria S.

J Clin Invest. 2012 Oct;122(10):3718-30. doi: 10.1172/JCI61931. Epub 2012 Sep 4.

13.

TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.

Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti SC, Barcellos-Hoff MH.

Clin Cancer Res. 2011 Nov 1;17(21):6754-65. doi: 10.1158/1078-0432.CCR-11-0544. Epub 2011 Oct 25.

14.

Research highlights: Immunotherapy.

Pilones KA, Demaria S.

Immunotherapy. 2009 Sep;1(5):733-6. doi: 10.2217/imt.09.53. No abstract available.

15.

Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade.

Pilones KA, Kawashima N, Yang AM, Babb JS, Formenti SC, Demaria S.

Clin Cancer Res. 2009 Jan 15;15(2):597-606. doi: 10.1158/1078-0432.CCR-08-1277.

Supplemental Content

Loading ...
Support Center